AEterna Zentaris

06/08/2024

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

https://bit.ly/3LXAFEc

TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic product...

18/07/2024

Visit our website at https://bit.ly/3BL7gpx to learn more about our pursuit of medical innovations.

Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of AGHD.

17/07/2024

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

https://bit.ly/4cJFFrN

TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthc...

16/07/2024

for all shareholders to join us for our Annual Meeting today at 10 AM ET. Shareholders can access the meeting by visiting: https://bit.ly/4bo7ZPf

AETERNA ZENTARIS INC. is hosting a Virtual Shareholder Meeting on Tuesday, July 16, 2024 at 10:00 am EDT, and the shareholders of record will be able to vote and ask questions online during the meeting. If you would like to attend the virtual meeting and have your control number, please log in 15 mi...

12/07/2024

Stay up to date on Aeterna Zentaris’ news and events by signing up for our email alerts here: https://bit.ly/3BG4lRZ

13/06/2024

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

https://bit.ly/45l54p5

TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthc...

03/06/2024

Aeterna Zentaris and Ceapro Complete Merger Transaction

https://bit.ly/4bYwVxa

TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company") and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) ("Ceapro"), two innovative biopharmaceutical development companies, are pleased to announce the successful completion and....

30/05/2024

Access investor resources here: https://bit.ly/3SIKvgc

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S...

30/05/2024

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that it is making....

23/05/2024

Visit our website at https://bit.ly/3BL7gpx to learn more about our pursuit of medical innovations.

17/05/2024

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

https://bit.ly/3wv5L2b

TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company") announces that it has finalized certain details regarding the previously announced merger of equals transaction (the "Transaction") with Ceapro Inc. ("Ceapro").

14/05/2024

Aeterna Zentaris Reports First Quarter 2024 Financial Results

https://bit.ly/44KhpCN

TORONTO, ONTARIO, May 14, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and o...

13/05/2024

Stay up to date on news regarding our merger here: https://bit.ly/3Q5WELT

09/05/2024

Stay up to date on Aeterna news and events by signing up for our email alerts here: https://bit.ly/3BG4lRZ

01/05/2024

Aeterna Zentaris Announces Effective Date of Share Consolidation

https://bit.ly/4dhHa17

TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company") announces that it has filed articles of amendment to effect the previously announced share consolidation (or reverse stock split) (the "Consolidation") of its issued and outsta...

28/03/2024

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

https://bit.ly/3TQGwjv

TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described i...

27/03/2024

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

https://bit.ly/3xkazqU

TORONTO, ONTARIO, March 27, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and...

12/03/2024

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

https://bit.ly/3IxCJ4c

TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of eq...